PD-161570;PF-1480232
PD-161570;PF-1480232 性质
| 熔点 | 215-230?C |
|---|---|
| 密度 | 1.249±0.06 g/cm3(Predicted) |
| 储存条件 | Store at RT |
| 溶解度 | 二甲基亚砜：>10mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 9.82±0.43(Predicted) |
| 颜色 | 白色至类白色 |
PD-161570;PF-1480232 用途与合成方法
|
FGFR1 39.9 nM (IC 50 ) |
FGFR1 42 nM (Ki) |
FGFR1 autophosphorylation 622 nM (IC 50 ) |
PDGFRβ 262 nM (IC 50 ) |
PDGFR 310 nM (IC 50 ) |
EGFR 240 nM (IC 50 ) |
c-Src 44 nM (IC 50 ) |
TGF-β Receptor
|
PD-161570 (Compound 6c; 0.1-1 µM; 1-8 days; VSMCs) treatment inhibits PDGF-stimulated vascular smooth muscle cell proliferation in a dose dependent fashion with an IC
50
of 0.3 µM on day 8.
PD-161570 suppresses constitutive phosphorylation of the FGF-1 receptor in both human ovarian carcinoma cells (A
121(p)
) and Sf9 insect cells overexpressing the human FGF-1 receptor and blocked the growth of A
121(p)
cells in culture.
PD-161570 can potently inhibit basic fibroblast growth factor (bFGF)-mediated angiogenesis.
Cell Proliferation Assay
| Cell Line: | Vascular smooth muscles cells (VSMCs) |
| Concentration: | 0.1 µM, 0.3 µM, 1 µM |
| Incubation Time: | 1 day, 3 days, 6 days, 8 days |
| Result: | Inhibited VSMC proliferation in a dose dependent fashion with an IC 50 of 0.3 µM at day 8. |
PD-161570;PF-1480232 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-100434 | 1 mg | 1028 | ||
| 2024-04-30 | P2531 | PD-161570;PF-1480232 | 192705-80-9 | 25MG | 1555 |
